Universidad Del País Vasco

Universidad Pablo De Olavide

Hospital Santiago Apóstol

Carlos Matute Almau

Ainara Vallejo Illarramendi

Maria Victoria Sanchez Gomez

Ana González Pinto

Aitor Palomino Fernández De Larrea

Alfredo Rodríguez-Antigüedad Zarranz

Pablo Villoslada Díaz

Ormaetxea Olatz Pampliega

Estibaliz Etxebarria Galnares

Fernando Pérez Cerdá

Alberto Pérez Samartín

María Domercq García

Rocio Leal Campanario

Agnes Gruart I Masso

Jose Maria Delgado Garcia

Gaskon Ibarretxe Bilbao

Miroslav Gottlieb

Elena Alberdi Alfonso

Rosario Campos Esparza

José María Delgado GARCÍA

María Victoria Sánchez Gómez

Rosario Upv Rectorado Campos Esparza

Gaskón Ibarretxe Bilbao

Agnès Gruart I Massó

Rocío Leal Campanario

The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds.

Compounds having neuroprotective properties

The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.

Method for the diagnosis and prognosis of demyelinating diseases

The invention describes an in vitro method for detecting a psychiatric disorder occurring with psychosis selected from schizophrenia and bipolar disorder in an individual who has suffered a first psychotic episode, or for determining the state or severity of said disorder, or for monitoring the effect of a therapy administered to an individual who suffers said disorder, or for evaluating the predisposition of an individual presenting a prodromal symptom to develop said disorder, based on the use of the brain-derived neutrophic factor (BDNF) as a marker.

Methods for diagnosis and prognostic of psychiatric diseases

Growing community of inventors

Leioa-Vizcaya, Spain

Carlos Matute Almau